Human Anti-NECTIN4 Recombinant Antibody (clone Enfortumab) (CAT#: TAB-H25)

This product is a human IgG1, κ antibody that can recognize human NECTIN4.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
FC

Figure 1 AGS-22M6 antibody specifically recognizes cell-surface human nectin-4 and its orthologs.

Cell counts of PC-3 cells expressing human, monkey, and rat nectin-4 (open histograms) were overlaid against mocktransfected PC-3 cells (solid histogram).

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

FC

Figure 2 FC measures the binding of AGS-22M6 antibody to human nectin-4.

Saturation curve of AGS-22M6 and AGS-22M6E binding to nectin-4 expressed on T-47D by flow cytometry shows KD of 0.01 nmol/L. MFI, mean fluorescence intensity

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Cyt

Figure 3 AGS-22M6E ADC shows potent and specific in vitro cytotoxicity.

PC-3 cells engineered to express human were incubated with increasing concentrations of unconjugated AGS-22M6.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Cyt

Figure 4 T-47D breast cancer cells were killed by AGS-22M6E ADC.

T-47D breast cancer cells, were incubated with increasing concentrations of unconjugated AGS-22M6.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Inhib

Figure 5 Nectin-4–targeted ADC shows significant tumor growth inhibition in multiple xenograft models.

AG-B1 subcutaneous xenografts treated with AGS-22M6E (or controls) at 0.8 mg/kg.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer researc 76(10), 3003-3013.

Inhib

Figure 6 AGS-22M6E ADC shows significant tumor growth inhibition in multiple xenograft models.

AG-Br7 orthotopic xenografts treated with AGS-22M6E (or controls) at 5 mg/kg.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer researc 76(10), 3003-3013.


Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • Human IgG1, κ
  • Specificity
  • Human NECTIN4
  • Species Reactivity
  • Human
  • Clone
  • Enfortumab
  • Applications
  • ELISA, Neut, IF, IP, FC, FuncS

Applications

  • Application Notes
  • This antibody has been reported for use in Enzyme-linked Immunosorbent Assay, Neutralization, Immunofluorescence, Immunoprecipitation, Flow Cytometry, Functional Assay.

Target

  • Alternative Names
  • LNIR; PRR4; EDSS1; PVRL4; nectin-4; nectin-4; Ig superfamily receptor LNIR; nectin 4; poliovirus receptor-related 4; poliovirus receptor-related protein 4

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Enfortumab Vedotin.

See other products for "NECTIN4"

See other products for "Clone Enfortumab"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2022 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart